

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2386 8100 (20 Lines)
Fax : +91-79-2386 2368
www.zyduscadila.com
CIN:L24230GJ195PLC025878

August 14, 2017

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 14, 2017 titled "Zydus announces settlement with Aptalis on CANASA* (mesalamine suppository, 1 g)".


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

for 
UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus announces settlement with Aptalis on CANASA[®] (mesalamine suppository, 1 g)

Ahmedabad, India, August 14, 2017

Cadila Healthcare Limited, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, today announced that the patent litigation relating to Aptalis's CANASA[®] (mesalamine suppository, 1 g) has been settled.

As a result of the settlement, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of CANASA[®] in the United States beginning on June 13, 2019, or earlier under certain circumstances.

Zydus Cadila previously received tentative approval from the USFDA to market its generic version of CANASA[®] (mesalamine suppository, 1 g). CANASA[®] is indicated to treat mildly to moderately active ulcerative colitis. Zydus Cadila's generic product will be produced at the group's Topical plant at Ahmedabad.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
